Jessica Brewster

Jessica Brewster

Auto-generated profile, based on publicly available information

Jessica Brewster

Australian Red Cross Lifeblood, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
JMJeremy S. McComish
Jeremy S. McComish
JBJessica Brewster
Jessica Brewster
ECEmma Carreiro
Emma Carreiro
KCKevin Chow
Kevin Chow
CHChristopher Hogan
Christopher Hogan
JDJames Daly
James Daly
De novo blood donor-specific human leukocyte antigen (HLA) antibodies (bDSA) from red cell transfusions can complicate solid organ transplantation, but the incidence rate is uncertain. We conducted a prospective observational study to assess the cumulative incidence rate of de novo bDSA in a cohort of patients with chronic kidney disease and no prior transplant, patients with prior kidney transplants (with or without continuing immunosuppression), and a general patient population. HLA antibody testing was performed before and 6 to 8 weeks after transfusion, with patient and blood donor typing. De novo HLA class 1 bDSA were detected in 10.8% (12 of 111) participants at a "weak" cutoff and in 7.2% (8 of 111) at a "moderate/strong" cutoff. De novo HLA class 2 bDSA were detected in 0.9% (1 of 111) at both cutoffs. Risk factors identified for HLA class 1 de novo bDSA included female sex (P < .001) and pretransfusion HLA antibodies (P = .02). The posttransplant group had low de novo bDSA (1 of 37, 2.7%). Additional testing suggested anamnestic (rather than de novo) responses in some participants. Red cell transfusions are associated with de novo bDSA, especially to HLA class 1 antigens, and measures to prevent sensitization, including selecting donors to avoid mismatches, may be warranted for some groups.